Quadrature Capital’s Altimmune ALT Stock Holding History

Quadrature Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,101	Closed	-$36.5K	–	1338
2025 Q4	$36.5K	Buy	+10,101	New	+$44K	﹤0.01%	1191

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Quadrature Capital's ALT Position: Q1 2026 in Review

Quadrature Capital sold out of Altimmune (ALT) in Q1 2026, closing a stake of 10,101 shares — an estimated $36.5K sold.

Quadrature Capital first reported a position in ALT in Q4 2025 and held it in 1 quarter. The position peaked at $36.5K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Quadrature Capital reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
Quadrature Capital sold 10,101 Altimmune shares in Q1 2026, an estimated $36.5K.
Quadrature Capital first reported a position in Altimmune in Q4 2025 and held it in 1 quarter.
Quadrature Capital's Altimmune position peaked at $36.5K in Q4 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.